Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study
Takanori Numata, Jun Araya, Hanae Miyagawa, et al.
Journal of Asthma and Allergy (2021) Vol. Volume 14, pp. 609-618
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy
Hiroyuki Nagase, Maho Suzukawa, Keiji Oishi, et al.
Allergology International (2022) Vol. 72, Iss. 1, pp. 11-23
Open Access | Times Cited: 56
Benralizumab for eosinophilic granulomatosis with polyangiitis
Adrien Cottu, Matthieu Groh, Charlene Desaintjean, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 12, pp. 1580-1586
Closed Access | Times Cited: 22
Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study
Takanori Numata, Jun Araya, Hanae Miyagawa, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 395-405
Open Access | Times Cited: 30
Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study
Takanori Numata, Jun Araya, Keitaro Okuda, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 1731-1741
Open Access | Times Cited: 26
Real-World Data on Tezepelumab in Patients With Severe Asthma in Germany
Leonie Biener, Carlo Mümmler, Christopher Alexander Hinze, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 9, pp. 2399-2407.e5
Closed Access | Times Cited: 4
Long-term, real-world effectiveness of biologics for severe uncontrolled asthma: The PROSPECT study
Kazuhisa Asai, Takashi Iwanaga, Mai Takahashi, et al.
Respiratory Investigation (2025) Vol. 63, Iss. 3, pp. 444-452
Open Access
Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP
Shunsuke Minagawa, Jun Araya, Naoaki Watanabe, et al.
BMC Pulmonary Medicine (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 21
Unanswered questions on the use of biologics in pediatric asthma
Antonio Nieto, Zeinab A. El-Sayed, René Maximiliano Gómez, et al.
World Allergy Organization Journal (2023) Vol. 16, Iss. 11, pp. 100837-100837
Open Access | Times Cited: 11
Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
Corrado Pelaia, Claudia Crimi, Santi Nolasco, et al.
Biomedicines (2021) Vol. 9, Iss. 12, pp. 1822-1822
Open Access | Times Cited: 23
Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
Luis Pérez de Llano, Borja G. Cosío, Ignacio Lobato Astiárraga, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 79-88
Open Access | Times Cited: 18
Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
A. Gómez-Bastero Fernández, Juan Francisco Medina Gallardo, Julio Delgado Romero, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 727-735
Open Access | Times Cited: 13
Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
Anne-Noëlle Frix, Liam G. Heaney, Barbro Dahlén, et al.
ERJ Open Research (2022) Vol. 8, Iss. 4, pp. 00273-2022
Open Access | Times Cited: 13
Long-term safety, durability of response, cessation and switching of biologics
Arjun Mohan, Anna Y. Qiu, Njira Lugogo
Current Opinion in Pulmonary Medicine (2024) Vol. 30, Iss. 3, pp. 303-312
Closed Access | Times Cited: 2
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
Paolo Cameli, Maria Aliani, Elena Altieri, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 273-290
Open Access | Times Cited: 2
Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort
Eve Denton, Mark Hew, Matthew Peters, et al.
Allergy (2024) Vol. 79, Iss. 10, pp. 2700-2716
Open Access | Times Cited: 2
Successful combination therapy of mepolizumab and dupilumab in a patient with EGPA: a future therapeutic option?
Joana Martins-Martinho, Roberto Pereira da Costa, Tiago Abreu, et al.
Rheumatology Advances in Practice (2024) Vol. 8, Iss. 3
Open Access | Times Cited: 2
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
Cristiano Caruso, Paolo Cameli, Elena Altieri, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 11
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
Giulia Scioscia, Pasquale Tondo, Santi Nolasco, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4362-4362
Open Access | Times Cited: 6
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
Paolo Solidoro, Stefania Nicola, Irene Ridolfi, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 200-200
Open Access | Times Cited: 10
Effectiveness of biologic switching in a real‐life, Belgian severe asthma cohort
Lucie Lafarge, Charles Pilette, Céline Bugli, et al.
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 10
Open Access | Times Cited: 1
Consensus on the management of united airways disease with type 2 inflammation: a multidisciplinary Delphi study
Marina Blanco–Aparicio, Javier Domínguez‐Ortega, Carolina Cisneros, et al.
Allergy Asthma and Clinical Immunology (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 4
Targeted Therapy for Severe Asthma: Switching Biological agents in Real Clinical Practice — Causes and Consequences
В. В. Наумова, Е. К. Beltyukov, D. V. Kiseleva, et al.
Russian Journal of Allergy (2023) Vol. 20, Iss. 4, pp. 439-454
Open Access | Times Cited: 4
Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients
María Sandra Domínguez-Sosa, María Soledad Cabrera-Ramírez, Miriam del Carmen Marrero-Ramos, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 1
Severe asthma in children
Adel S. Alharbi, Abdullah A. Yousef, Saleh Alharbi, et al.
Saudi Medical Journal (2022) Vol. 43, Iss. 4, pp. 329-340
Open Access | Times Cited: 6
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study
Yuji Tohda, Yoichi Nakamura, Takao Fujisawa, et al.
Allergology International (2022) Vol. 72, Iss. 1, pp. 89-99
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top